FMTVDM©℗ provides first patented quantitative method to accurately measure both heart disease and breast cancer on the “Health-Spectrum”

Sheikine Y, Berman DS, DiCarli F (2010) Technetium-99m-sestamibi redistribution after exercise stress test identified by a novel cardiac gamma camera: Two case reports. Clin. Cardiol 33: E39-45. Link: https://bit.ly/2WSj6yh

Fleming RM, Chaudhuri TK, McKusick A (2019) The FDA, HHS, Sestamibi Redistribution and Quantification. AS Pharm Sci 3: 47-69. Link: https://bit.ly/2L4u4db

Won KS, Jo II, Kim SH (2012) Five-minutes post-stress gated myocardial perfusion SPECT using Tc-99m tetrofosmin. J Nucl Med 53: 1831. Link: https://bit.ly/2IRaT3O

Grady D, Chaput L, Kristof M (2003) Diagnosis and treatment of coronary heart disease in women: Systematic review of evidence on selected topics. Evidence report/technology assessment Number 81. (Prepared by the University of California, San Francisco-Stanford evidence-based practice center under Contract No. 290-97-0013.) AHRQ Publication No. 03-E037. Rockville, MD: Agency for Healthcare Research and Quality. Link: www.ahrq.gov

Bruening W, Launders J, Pinkney N, Kostinsky H, Schoelles K, et al. (2006) Comparative Effectiveness Review. Number 2: Effectiveness of Noninvasive Diagnostic Tests for Breast Abnormalities. (Prepared for the Agency for Healthcare Research and Quality, U.S. Dept of Health and Human Services). AHRQ Publication No. 06-EHC005-EF. Link: www.ahrq.gov